# OptiBiotix Health Plc Non-Exclusive European License Agreement with Nutrilinea

- Link: https://www.directorstalkinterviews.com/optibiotix-health-plc-non-exclusive-european-license-agreement-nutrilinea/412728825
- Published: 2017-05-09T07:05:42+01:00
- Author: Giles Arbor

**OptiBiotix Health plc** (LON:OPTI), a life sciences business developing compounds
to tackle obesity, high cholesterol, diabetes and skin care, announced today that
it has agreed to grant a non-exclusive license agreement to Nutrilinea for the production
and commercialisation of products containing OptiBiotix’s LPLDL® strain in Europe
with a view to maximising the financial return for both parties.

Nutrilinea has over 15 years’ experience in the design and development of customised
formulations and presentations (capsules, tablets, sachets) for the supplement and
pharmaceutical industry. Nutrilinea provides products to both national and international
businesses in Europe and the USA, and is one of Europe’s fastest growing providers
of food supplements, doubling revenues in the last 12 months to over €30m per annum.

Nutrilinea is based in Italy and has established an international reputation for
providing innovative product formulations and presentations for different markets,
including products containing some of the world’s best selling probiotic strains.
Nutrilinea intends to produce proprietary formulations containing OptiBiotix’s LPLDL
® strain developed to reduce cholesterol levels and blood pressure (CholBiome™),
and cardiovascular risk (CardioBiome™). Under the terms of the agreement, Nutrilinea
intends to produce, promote, market and commercialise OptiBiotix’s CholBiome™ and
CardioBiome™ products to their European network with the aim of maximising the financial
return for both parties.

This pre-launch agreement is another step in a business to business (B2B) strategy
of bringing OptiBiotix’s science together with partner’s expertise and market reach
to serve multiple consumer healthcare and pharmaceutical markets around the world.

> **Stephen O’Hara, CEO of OptiBiotix Health Plc, commented:** “We are pleased to
> announce this non-exclusive license agreement with Nutrilinea for the production
> and commercialisation of products containing OptiBiotix’s LPLDL® strain for the
> reduction of cholesterol and cardiovascular risk. We chose Nutrilinea due to its
> industry reputation, extensive European network, and record of doubling revenues
> in the last 12 months. We believe working with Nutrilinea, and similar partners
> around the world, provide the best opportunity of building LPLDL® into a global
> brand. We see this as another step in building revenues and market presence of
> LPLDL® as the ‘Intel’ inside a wide range of products, provided in different presentations
> and formulations, for cardiovascular health across both consumer and pharmaceutical
> markets around the world.”

Share on: